Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent advances in neuroproteomics.

Erika C Andrade1, Dilja D Krueger, Angus C Nairn

  • 1Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06508, USA.

Current Opinion in Molecular Therapeutics
|July 5, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

mPFC Synaptosome Proteomics Reveals Novel Pathways and Muscarinic Receptor Changes in a Learned Helplessness Mouse Model.

eNeuro·2026
Same author

mPFC Synaptosome Proteomics Reveals Novel Pathways and Muscarinic Receptor Changes in a Learned Helplessness Mouse Model.

bioRxiv : the preprint server for biology·2026
Same author

Devaluation of response-produced safety signals reveals circuits for goal-directed versus habitual avoidance in dorsal striatum.

Nature communications·2026
Same author

Basic Science and Pathogenesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Ryanodine receptor 2-mediated calcium leak is associated with increased glyoxalase I in the aging brain.

JCI insight·2025
Same author

Myelin-axon interface vulnerability in Alzheimer's disease revealed by subcellular proteomics and imaging of human and mouse brain.

Nature neuroscience·2025
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

Neuroproteomics uses advanced methods to study brain function and disease. This review covers recent progress and challenges in analyzing neuronal protein expression.

Area of Science:

  • Neuroscience
  • Proteomics
  • Biochemistry

Background:

  • Proteomic methods are increasingly used to investigate normal brain function.
  • These techniques also analyze protein expression changes in neurodegenerative diseases.
  • The central nervous system's complexity presents unique challenges for neuroproteomics.

Purpose of the Study:

  • To review recent advancements in neuroproteomics research.
  • To highlight the capabilities and constraints of current proteomic technologies for studying neuronal proteins.

Main Methods:

  • Review of recent literature on proteomic profiling technologies.
  • Analysis of applications in studying normal and diseased brain states.
  • Discussion of challenges specific to the central nervous system.

Related Experiment Videos

Main Results:

  • Rapid growth in proteomic applications for neuroscience.
  • Identification of protein expression alterations in neuronal diseases.
  • Evaluation of current proteomic technology strengths and limitations.

Conclusions:

  • Neuroproteomics is a rapidly evolving field with significant potential.
  • Understanding proteomic technology limitations is crucial for accurate neuronal studies.
  • Continued technological development is needed to overcome CNS complexity.